A bout 64% of individuals develop chemotherapy-induced peripheral neuropathy (CIPN) following treatment with neurotoxic chemotherapeutic agents, such as taxanes, platinums, and vinca alkaloids (Seretny et al., 2014). CIPN is mainly a sensory, length-dependent neuropathy affecting sensory, motor, and autonomic peripheral nerves and is most commonly characterized by numbness, tingling, and neuropathic pain in the extremities. Symmetrical neuropathic pain; altered touch, temperature, and vibration sensibility; and diminished proprioception are characteristics of sensory CIPN, whereas motor CIPN is characterized by weakness and muscle atrophy. Diminished deep tendon reflexes indicate sensory and motor CIPN. Autonomic CIPN symptoms are less common and include constipation, orthostatic hypotension, Research Approach: Cross-sectional, prospective, qualitative design.
Participants: 25 adults with multiple myeloma or breast, gynecologic, gastrointestinal, or head and neck malignancies experiencing peripheral neuropathy caused by neurotoxic chemotherapy.
Methodologic Approach: Cognitive interviewing methodology was used to evaluate the content validity of a 16-item version of the QLQ-CIPN20 instrument.
Findings: Minor changes were made to three questions to enhance readability. Twelve questions were revised to define unfamiliar terminology, clarify the location of neuropathy, and emphasize important aspects. One question was deleted because of clinical and conceptual redundancy with other items, as well as concerns regarding generalizability and social desirability.
Interpretation: Cognitive interviewing methodology revealed inconsistencies between patients' understanding and researchers' intent, along with points that required clarification to avoid misunderstanding. Implications for Nursing: Patients' interpretations of the instrument's items were inconsistent with the intended meanings of the questions. One item was dropped and others were revised, resulting in greater consistency in how patients, clinicians, and researchers interpreted the items' meanings and improving the instrument's content validity. Following additional revision and psychometric testing, the QLQ-CIPN20 could evolve into a goldstandard CIPN patient-reported outcome measure. 
